Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech which has proved helpful diligently but unsuccessfully to develop an one off therapy, variously named Pro 140, leronlimab, as well as Vyrologix.

In development of this therapy, CytoDyn has cast its net wide and far both geographically and in terms of prospective indications.

CytoDyn’s inventories of leronlimab are building up, whether they will actually be being used is an open question.

While CYDY  is actually dawdling, market opportunities for leronlimab as a combination therapy in the healing of multi-drug-resistant HIV happen to be closing.

I’m writing my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale of my past few shares. The 1st CytoDyn post of mine, “CytoDyn: What To Do When It is Too Good to be able to Be True?”, set out all of the following prediction:

Instead I expect it to be a serial disappointer. CEO Pourhassan presented such an extremely marketing image in the Uptick Newswire job interview which I came away with a poor impression of the business.

Irony of irony, the poor opinion of mine of the business has grown steadily, yet the disappointment has not been financial. Two decades ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades during $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is it that gives a > 6 bagger at the moment still disappoints? Therein lies the story; permit me to explain.

CytoDyn acquired its much storied treatment (which I shall mean as leronlimab) back throughout 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor of the therapy as well as prevention of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical development mAb with demonstrated anti-viral activity of HIV- infected subjects. Today’s transaction of $3.5 zillion transfers ownership of this know-how and also associated intellectual property coming from Progenics to CytoDyn, and also approximately 25 million mg of majority drug substance…. milestone payments after commencement of a level III clinical trial ($1.5 zillion) and also the first new drug application approval ($five million), as well as royalty payments of 5 % of net sales upon commercialization.

Since that point in time, CytoDyn’s leading nous, Nader Pourhassan [NP] has made this inauspicious acquisition right into a springboard for CytoDyn to buy a market cap > $3.5 billion. It’s done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with many indications and numerous therapies, it has this individual treatment in addition to a “broad pipeline of indications” because it puts it. I call certain pipelines, “pipedots.” In CytoDyn’s case it touts the leronlimab of its as a potentially beneficial therapy in dozens of indications.

The opening banner of its on its website (below) shows an energetic company with diverse interests albeit focused on leronlimab, several disease types, multiple publications and multiple delivering presentations.

Might all of it be smoke cigarettes and mirrors? That’s a question I have been asking myself through the really start of the interest of mine in this particular business. Judging by way of the multiples of a huge number of diverse comments on listings accessible through Seeking Alpha’s CytoDyn Summary webpage, I’m much from alone in this question.

CytoDyn is a traditional battleground, or some may say cult inventory. Its adherents are fiercely shielding of the prospects of its, quick to label some bad opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *